Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...
Healio

‘Important discovery’ shows how complement cascade drives systemic inflammation

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Healio

Alternative complement pathway inhibition may be key to lupus management

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...